Canakinumab as first-line biological therapy in Still's disease and differences between the systemic and the chronic-articular courses: real-life experience from the international AIDA registry.

Vitale, A; Caggiano, V; Maggio, Mc; Lopalco, G; Emmi, G; Sota, J; La Torre, F; Ruscitti, P; Bartoloni, E; Conti, G; Fabiani, C; Mattioli, I; Gaggiano, C; Cardinale, F; Dagna, L; Campochiaro, C; Giacomelli, R; Balistreri, A; Laskari, K; Tufan, A; Ragab, G; Almaghlouth, Ia; Więsik-Szewczyk, E; Pereira, Rm; Frediani, B; Iannone, F; Sfikakis, Pp; Cantarini, L.